Background
Reduction in 3-point MACE | Reduction in CV death | Reduction in all-cause mortality | Reduction in hospitalisation for HF | Reduction in doubling of serum creatinine | |
---|---|---|---|---|---|
EMPA-REG OUTCOME®
| |||||
RRR (%) | 14 | 38 | 32 | 35 | 44 |
p value | 0.04 | < 0.001 | < 0.001 | 0.002 | < 0.001 |
LEADER®
| |||||
RRR (%) | 13 | 22 | 15 | 13 | 12 |
p value | 0.01 | 0.007 | 0.02 | NS | NS |
SUSTAIN™-6 | |||||
RRR (%) | 26 | 2 | + 5 | + 11 | + 28 |
p value | 0.02 | NS | NS | NS | NS |
Methods
Recommendations of CEEDEG
Diagnosis/assessment
-
Clinical: blood pressure sitting and standing, and classification of heart failure (HF) according to New York Heart Association functional criteria [27].
-
Laboratory:
-
HbA1c levels; lipid profile; glomerular filtration rate (GFR)/estimated GFR (eGFR), urinary albumin/creatinine ratio (UACR) and proteinuria.
-
For patients with CKD, urinalysis.
-
Brain natriuretic peptide (BNP)/N-terminal prohormone of BNP (NT-proBNP) should be considered in patients having symptoms or signs of HF.
-
Other causes/kidney diseases associated with macroalbuminuria, including the detection of nondiabetic nephropathy, should be ruled out.
-
Physiological measurements:
-
For patients who are at particular risk of MI, electrocardiogram (ECG) should be performed.
-
For patients with CKD, kidney/cardiac ultrasound should be considered depending on clinical need.
-
-
Clinical management
Adherence rates and patient education
-
Therapeutic choices should be explored with the patient, making use of decision aids where relevant, and should take place within the context of the patient’s priorities, goals and preferred level of involvement.
-
Treatment strategies should be kept as simple as possible to reduce the apparent treatment burden, e.g. the use of dual-agent therapies.
-
Treatments should be carefully and thoroughly explained to patients on multiple occasions, and reiterated by all practitioners involved in the patient’s care.
-
The patient’s age should also be considered when selecting treatment, taking into account age-related comorbidities and the special repercussions of possible adverse events, such as falls in elderly or frail patients.
-
Full dietary evaluation (rather than simple caloric intake) should be performed for all patients.
-
The agreed management program should then be implemented and run by clinical specialists and primary care physicians, ideally involving a dietitian and, if needed, a psychologist (Table 2).Table 2Specialities for inter-professional, multidisciplinary team-based type 2 diabetes care for a comprehensive multifactorial risk-reduction strategy in the context of cardiovascular comorbiditySpecialityKey functions and areas of responsibilityDiabetologist/endocrinologistTherapy induction including patient education: explanation of therapy choice, side-effects, complications, acute emergenciesSets BP, lipid, HbA1c targetsTrained in cardiology/nephrology/internal medicineInternistFollow-up care, including monitoring of BP, lipid targets and controls, ECG, echocardiagram imagingTrained in diabetology (patients with diabetes who are complicated to treat should always be referred to diabetologists/endocrinologists)NephrologistRenal function, ACR, BP controlLipid targetsCardiologistEssential for CVD and CV risk managementTrained in diabetologyNutritionist/dieticianDietary counselling at therapy inductionA key figure in patient education together with diabetologist/endocrinologistMonitoring of glucose control and intake, and body weightIndividual diet plans for weight reduction if needed, and/or long-term weight maintenanceNursesEducation programmesIndividual supportBMI monitoringCertified diabetes educatorSmoking cessationDiabetes education at treatment induction and for re-enforcementEducation programmes, team workConsistent and structured education that is crucial for adherence, motivation and minimising barriers to treatment
Glycaemic control
Cardiovascular protection
Type 2 diabetes therapeutic regimens
Monotherapy
Combination therapy
Class | Beneficial effect on CV outcomes | Beneficial effect on HbA1c levels | Effect on weight | Hypoglycaemic risk |
---|---|---|---|---|
Metformin (oral) | Moderate (long-term) | Moderate | Moderate decrease | Neutral |
SGLT2 inhibitors (oral) | ||||
Empagliflozin
e
| High (empagliflozin and canagliflozin) | Moderate to high | High decrease | Neutral |
Canagliflozin | ||||
Dapagliflozin | ||||
GLP-1 receptor agonists (injection) | ||||
Liraglutide
| High (liraglutide and semaglutide) | High | Very high decrease | Neutral |
Semaglutide | ||||
Exenatide | ||||
Exenatide LAR | ||||
Dulaglutidea
| ||||
DPP-4 inhibitors (oral) | ||||
Sitagliptin
e
| Neutral | Moderate | Neutral | Neutral |
Alogliptine
| ||||
Linagliptine
| ||||
Saxagliptin | ||||
Vildagliptine
| ||||
Insulins (injection) | ||||
Insulin degludec
| Neutral | High | Neutral | High |
Insulin glargine
| ||||
TZDs (oral) | ||||
Pioglitazone | High?b
| Moderate?c
| Increased
| |
SUs (oral) | ||||
Gliclazide
| Neutral | Moderate | Neutral | Moderate |
Glimepiride |
Dual therapy
SGLT2 inhibitors
GLP-1 receptor agonists
DPP-4 inhibitors
Insulin
Other type 2 diabetes treatment agents
Triple therapy
Monitoring/evaluation of response to treatment
Cardiac/lipid control
Special prescribing considerations
Elderly patients
Class effect
Antidiabetic drug | 3P-MACE hazard ratio (HR) |
p value | |
---|---|---|---|
PROactive | Pioglitazone | 0.84 (95% CI 0.72–0.98) | 0.02 |
ORIGIN | Insulin glargine | 1.02 (95% CI 0.94–1.11) | NS |
SAVOR | Saxagliptin | 1.00 (95% CI 0.89–1.12) | NS |
EXAMINE | Alogliptin | 0.96 (95% CI 0.80–1.15) | NS |
ELIXA | Lixisenatide | 1.02 (95% CI 0.89–1.17) | NS |
TECOS | Sitagliptin | 0.98 (95% CI 0.89–1.08) | NS |
EMPA-REG OUTCOME®
| Empagliflozin | 0.86 (95% CI 0.74–0.99) | 0.038 |
LEADER®
| Liraglutide | 0.87 (95% CI 0.78–0.97) | 0.01 |
SUSTAIN™-6 | Semaglutide | 0.74 (95% CI 0.58–0.95) | < 0.001a
|
CANVAS-program | Canagliflozin | 0.86 (95% CI 0.75–0.97) | 0.02 |